We report a patient with bile duct carcinoma with longer than 13-year survival with no surgical treatment but cholangioscopic MTC.
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Shigeaki Ino-u-e 1) , Takashi Fukushima 2) , Masaaki Endoh 3) , Shoichi Shida 4) , Hiromichi Nakachi 4) , Yuuichi Ebina 4) , Shuuichi Yoshihara 4) Introduction Bile duct carcinoma is one of the most lethal and aggressive malignancies, with the majority of patients harboring unresectable tumors at presentation.
The current conventional treatment for bile duct carcinoma is either bile duct resection with hepatectomy or pancreatoduodenectomy based on its location according to the guidelines for diagnosis and treatment of bile duct carcinomas 1) . However, there has been no expectation of long-term survival of more than 5 years without resection for a jaundiced patient with bile duct carcinoma.
We report a patient with bile duct carcinoma with longer than 13-year survival with no surgical treatment but cholangioscopic MTC. Although cholangioscopic MTC is a palliative procedure for bile duct carcinoma, it could be an alternative means of non-operative management of highly risky patients with bile duct carcinoma.
Case
A 67-year-old female who had undergone coronary arterial bypass grafting (CABG) was referred to our institution because of increased obstructive jaundice with suspected bile duct carcinoma. Percutaneous transhepatic cholangial drainage (PTCD) was conducted for biliary decompression and improvement of her jaundice, followed by detection of a fluorographic filling defect in the middle and lower bile duct, which suggested complete obstruction (Fig. 1) .
Computed tomography (CT) and ultrasonography (US)
examinations revealed no metastatic regional lymph node involvement.
Employing step-wise dilatation of the PTCD sinus tract, percutaneous transhepatic cholangioscopy (PTCS) revealed a papillary tumor in the common bile duct (CBD), which resulted in the histological diagnosis of papillary ade-
Because she had undergone CABG using pedicle right gastroepiploic artery, it was not possible to apply pancreatoduodenectomy as radical operation.
Therefore, cholangioscopic and X-ray image-guided MTC using Microtaze (Heiwa Electronic Industrial Co. Ltd., Osaka, Japan) and 1.8 mm spherical, 5 mm bulletshaped antennas was carried out under radiation of 45 watts and repetitions of 3-5 second duration ( Fig. 3) 2)
. After complete re-canalization of the CBD and lack of malignant lesions on biopsy, an indwelling tube (16 Fr, Create Medic Co. Ltd., Kanagawa, Japan) was left in place in the sinus tract for the .
No adverse effects of MTC were noted in this patient.
Major side effects of this treatment such as ductal perforation and vessel injury do not occur in mild MTC treatment but may occur in the sinus-tract-making and dilating interventions of PTCD and PTCS. Careful and gentle maneuvers utilizing an advanced US system, which can discriminate the sinus tract, bile duct, and blood vessels precisely, will be able to achieve intervention with less invasion.
Initially, MTC was used as palliative, symptomatic treatment for patients with bile duct neoplasms with obstructive jaundice, and in a female patient, MTC was performed safely, achieving a long survival of more than 10 years. MTC may be useful for palliation of inoperable patients with bile duct carcinoma, and sometimes for cure of the patients in the early stage of progression.
